Quality Bioresources

Quality Bioresources

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Quality BioResources is a specialized contract manufacturer providing critical lyophilization services to diverse life science and consumer industries. The company leverages a 30,000+ square foot facility in Texas, featuring industrial-scale lyophilizers and ISO 13485 certification for medical device manufacturing, positioning it as a key partner for sensitive biologics, diagnostics, and biomaterials. Its business model is purely service-based, generating revenue through contract manufacturing without developing its own therapeutic or diagnostic products. QBI's value proposition centers on scalability, quality assurance, and decades of formulation expertise for complex freeze-drying applications.

DiagnosticsAntibodies

Technology Platform

Industrial-scale lyophilization (freeze-drying) and custom formulation services for stabilizing sensitive biologicals, diagnostics, and biomaterials. Includes cycle development, filling, and biomaterials processing.

Opportunities

Growing demand for outsourced lyophilization from the expanding biopharma, diagnostic, and advanced biomaterials sectors.
Its specialization in diagnostics and central US location provide a niche advantage over larger, more generalized CDMOs.
ISO 13485 certification is a key enabler for regulated medical device contracts.

Risk Factors

Revenue is project-based and susceptible to client attrition or project completion gaps.
Operating in regulated (FDA, ISO) spaces exposes the company to significant compliance and quality failure risks.
Intense competition from other CDMOs and potential client in-sourcing threaten market share.

Competitive Landscape

QBI competes with other specialized lyophilization CDMOs and broader contract manufacturing organizations (CMOs). Its differentiation lies in its specific focus on diagnostics, biomaterials, and cosmetics, its claimed scalable capacity in the central US, and its ISO 13485 certification. It likely competes on flexibility, technical expertise in formulation, and cost for small-to-mid volume runs.